Related Experiment Video
Updated: Jan 28, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
Antiretroviral Resistance Patterns in Children with HIV Infection
1Paediatric Infectious Diseases Unit, Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, University of Cape Town, Rondebosch, Cape Town, 7700, South Africa. james.nuttall@uct.ac.za.
Insights
High HIV drug resistance in children, especially to NNRTIs, leads to poor outcomes. New dolutegravir regimens offer hope for improved treatment in low-income countries.
Area of Science:
- Pediatric infectious diseases
- HIV/AIDS research
- Pharmacology
Background:
- HIV drug resistance is a growing concern in children.
- Understanding resistance patterns is crucial for effective treatment.
Purpose of the Study:
- To update on HIV drug resistance patterns in children.
- Focus on pretreatment and acquired drug resistance (PDR/ADR).
- Emphasis on low- and middle-income countries (LMICs).
Main Methods:
- Review of recent data on HIV drug resistance in pediatric populations.
- Analysis of treatment outcomes with various antiretroviral regimens.
Main Results:
- High PDR to NNRTIs reported, linked to poor outcomes on NNRTI-based ART.
- Limited data on PI-based regimens show tolerability and resistance issues.
- Lack of virological monitoring and resistance testing delays treatment adjustments.
- Dolutegravir-based regimens show promise but require child-friendly formulations and completed studies.
Conclusions:
- Effective ART regimens with higher resistance barriers are needed for global targets.
- PI-based regimens face formulation, tolerability, and cost challenges in LMICs.
- Dolutegravir-based regimens are expected to improve pediatric HIV treatment outcomes.
Purpose Of Review:
To provide an update on the patterns of HIV drug resistance in children, including pretreatment drug resistance (PDR) and acquired drug resistance (ADR), focusing on children in low- and middle-income countries (LMICs) for whom empiric first-line (FL) and second-line (SL) antiretroviral regimens are usually recommended.
Recent Findings:
High levels of PDR, particularly to non-nucleoside reverse transcriptase inhibitors (NNRTIs), and poor treatment outcomes on NNRTI-based FL antiretroviral therapy (ART) have been widely reported among infants and young children. There is a paucity of recent data on the use of protease inhibitor (PI)-based FL and SL regimens in children, but studies have reported poor tolerability, adherence problems and the development of PI resistance. Limited access to virological monitoring and HIV drug resistance testing contributes to delays in identifying treatment failure due to ADR and delays in switching to SL regimens in children. Implementation of FL ART regimens that have a higher barrier to developing resistance and are safe and well tolerated is required in order to attain global treatment targets. Although PI-based regimens may be effective as FL or SL treatment in children, lack of appropriate formulations leading to poor tolerability, drug-drug interactions, and cost considerations have negatively impacted their use among children in LMICs. There is hope that dolutegravir-based regimens recommended for children by the World Health Organization will be widely implemented once child-friendly formulations are available, and dosing and safety studies currently underway are completed, and that this will significantly improve treatment outcomes.
More Related Videos
Related Concept Videos
Resistivity
Resistance
Fixed Action Patterns
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...
Equivalent Resistance
Patterns of Fever

